Cite
Feld J, Tremblay D, Dougherty M, et al. Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies. Hemasphere. 2021;5(4):e549doi: 10.1097/HS9.0000000000000549.
Feld, J., Tremblay, D., Dougherty, M., Czaplinska, T., Sanchez, G., Brady, C., Kremyanskaya, M., Bar-Natan, M., Keyzner, A., Marcellino, B. K., Gabrilove, J., Navada, S. C., Silverman, L. R., El Jamal, S. M., Mascarenhas, J., & Shih, A. H. (2021). Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies. HemaSphere, 5(4), e549. https://doi.org/10.1097/HS9.0000000000000549
Feld, Jonathan, et al. "Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies." HemaSphere vol. 5,4 (2021): e549. doi: https://doi.org/10.1097/HS9.0000000000000549
Feld J, Tremblay D, Dougherty M, Czaplinska T, Sanchez G, Brady C, Kremyanskaya M, Bar-Natan M, Keyzner A, Marcellino BK, Gabrilove J, Navada SC, Silverman LR, El Jamal SM, Mascarenhas J, Shih AH. Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies. Hemasphere. 2021 Mar 09;5(4):e549. doi: 10.1097/HS9.0000000000000549. eCollection 2021 Apr. PMID: 33718803; PMCID: PMC7951133.
Copy
Download .nbib